David T. Weaver

Patterns of duvelisib‐induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high‐risk factors, in the DUO trial

Purpose of the Study: Lymphocytosis is a defining feature of chronic lymphocytic leukemia (CLL) and recognized as a class effect of treatment with B‐cell receptor pathway inhibitors....

Jacqueline Barrientos ;

Ian W. Flinn ;

Amanda Cashen ;

Nicholas Chiorazzi ;

Shih Chen ;

Samantha Hidy ;

Johnathan Pachter ;

Jennifer R. Brown ;

Matthew S. Davids , MD, MMSc;

David T. Weaver ;

Stephanie Lustgarten ;

10/23/2019

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Peter Hillmen ;

Marco Montillo ;

Florence Cymbalista ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Matthew S. Davids , MD, MMSc;

Ian W. Flinn ;

Julio Delgado ;

Bryone J. Kuss ;

10/23/2019

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Ian W. Flinn ;

Peter Hillmen ;

Julio Delgado ;

Marco Montillo ;

Bryone J. Kuss ;

Florence Cymbalista ;

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Matthew S. Davids , MD, MMSc;

10/23/2019

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

Hagop Youssoufian ;

Ian W. Flinn ;

Julio Delgado ;

Bryone J. Kuss ;

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Peter Hillmen ;

Marco Montillo ;

Florence Cymbalista ;

David T. Weaver ;

Matthew S. Davids , MD, MMSc;

Stephanie Lustgarten ;

10/23/2019

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Purpose of the Study: Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/smal...

Julio Delgado ;

Bryone J. Kuss ;

Constantine S. Tam ;

Francesc Bosch ;

Ulrich Jager ;

Paolo Ghia ;

Florence Cymalista ;

Stephan Stilgenbauer ;

Fritz Offner ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Ian W. Flinn ;

Nicole Lamanna ;

Marco Montilo ;

Matthew S. Davids , MD, MMSc;

Gabriel Etienne ;

10/22/2019

Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial

Purpose of the Study: Duvelisib, a first-in-class oral dual PI3K-, inhibi- tor, was approved by the US FDA for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) o...

Gerardo Musuraca ;

Michele Merli ;

Roberto Marasca ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Pier Luigi Zinzani ;

Eric Jacobsen ;

Juraj Ura ;

Kirit Ardeshna ;

Mohamad Cherry ;

Fritz Offner ;

Jiri Mayer ;

Fontanet Bijou ;

Monica Tani ;

10/22/2019

Patterns of duvelisib‐induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high‐risk factors, in the DUO trial

Purpose of the Study: Lymphocytosis is a defining feature of chronic lymphocytic leukemia (CLL) and recognized as a class effect of treatment with B‐cell receptor pathway inhibitors....

Shih Chen ;

Samantha Hidy ;

Johnathan Pachter ;

Jennifer R. Brown ;

Matthew S. Davids , MD, MMSc;

David T. Weaver ;

Stephanie Lustgarten ;

Jacqueline Barrientos ;

Ian W. Flinn ;

Amanda Cashen ;

Nicholas Chiorazzi ;

10/23/2019